MedTrace Logo

Phase 1 Study in Patients With Advanced and/or Refractory Solid Malignancies to Evaluate the Safety of ATOR-1015

NCT03782467 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2022-08-18

No results posted yet for this study

Summary

The aim of the study is to investigate the safety and tolerability of ATOR-1015 when administered as repeated intravenous infusions to patients with advanced and/or refractory solid malignancies.

Conditions

Interventions

BIOLOGICAL

ATOR-1015

Bispecific human monoclonal antibody targeting cytotoxic T-lymphocyte associated protein 4 (CTLA-4) and OX40 (also known as CD134)

Sponsors & Collaborators

  • Alligator Bioscience AB

    lead INDUSTRY

Principal Investigators

  • Malin Carlsson, MD · Alligator Bioscience AB

  • Jeffrey Yachnin, Dr · Centrum för Kliniska Cancerstudier (CKC), Karolinska Universitetssjukhuset

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-30
Primary Completion
2021-03-03
Completion
2021-03-03

Countries

  • Denmark
  • Sweden

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03782467 on ClinicalTrials.gov